Vivesto AB, a pharmaceutical company based in Sweden, specializes in developing innovative treatment options for challenging cancer cases. With a Risk Rating Score of 25.6, the company is considered to have a medium risk level. Vivesto AB focuses on creating new drug formulations using advanced technology platforms to improve treatment effectiveness and reduce side effects. Their portfolio includes various projects aimed at enhancing cancer therapies.